R. Goldie (Crawley, Australia), C-G. Löfdahl (Lund, Sweden)
Is flow dependent dose delivery of a salbutamol-Turbuhaler clinically relevant in asthma patients?
M. E. A. C. Broeders, J. Schalkwijk, J. Molema, H. T. M. Folgering (Groesbeek, The Netherlands)
|  |
Formoterol: a new pMDI CFC free formulation. Efficacy of the 12µg dosage versus a dry powder inhaler in moderate to severe asthmatic patients
J. Bousquet, G. Huchon, V. Leclerc, E. Vicaut, G. Lefrancois, P. A. Monici Preti (Montpellier, Paris, Courbevoie, France; Parma, Italy)
| |
Formoterol hydrofluoroalkane (HFA) pMDI has as rapid an onset of action as salbutamol HFA pMDI in asthma
J. Lötvall, J. Ankerst, S. Cassidy, N. Byrne (Gothenburg, Lund, Sweden; Loughborough, United Kingdom)
| |
Safety and tolerability of high-dose formoterol via aerolizer and salbutamol via MDI in patients with mild-to-moderate COPD
S. Fitoussi, C. Dobson, G. Ayre, W. Langholff (Rueil-Malmaison, France; Horsham, United Kingdom; East Hanover, United States Of America)
| |
A single dose of formoterol (FOR) and tiotropium (TIO) reduce lung hyperinflation in COPD patiens: preliminary data
F. Di Marco, P. Carlucci, M. Cazzola, M. Verga, M. Mondoni, A. Pistone, B. Boveri, S. Centanni (Milan, Naple, Italy)
| |
Onset of action of tiotropium (TIO) + formoterol (FOR) in patients with stable COPD
F. Di Marco, P. Santus, B. Boveri, M. Verga, M. G. Matera, S. Centanni, M. Cazzola (Milan, Naples, Italy)
| |
Effects of regular formoterol treatment on airway hyperresponsiveness in patients with mild to moderate asthma
C. Tálamo, A. Acuña, D. Hurtado, M. MontesdeOca (Caracas, Venezuela)
| |
Onset of action of salmeterol/fluticasone (SFC) in single inhaler vs. salmeterol (S) in patients with COPD
P. Santus, M. G. Matera, P. Carlucci, E. Belloni, M. Mondoni, S. Centanni, M. Cazzola (Milan, Naples, Italy)
| |
Comparative study of one-year treatment with salmeterol along, and in combination with ipratropium bromide and beclometazone dipropionate in patients with chronic obstructi e pulmonary diseases (COPD)
D. V. Djordjevic, D. S. Zivkovic, I. J. Stankovic, T. A. Pejcic, M. H. Rancic, L. M. Ristic (Nis, Yugoslavia)
| |
The tulobuterol patch using a transdermal delivery system improves oxygen desaturation during exercise performance in severe COPD patients
M. Miura, T. Adachi, S. Akai (Sendai, Japan)
| |
Effect of oral procaterol on allergic inflammation examined by a murine asthmatic model
N. Yamashita, H. Ishida, J. Nakano, H. Tashimo, M. Nakajima, F. Kaneko, K. Ohta (Tokyo, Japan)
| |
Inhibitory effects of formoterol, budesonide and tiotropium bromide on human neutrophils in vitro
C. Feistritzer, C. Molnar, C. J. Wiedermann, C. M. Kähler (Innsbruck, Austria)
| |
Proteoglycan production in cultured human lung fibroblasts is synergistcally inhibited by combination of budesonide and formoterol
L. Todorova, A. Miller-Larsson, J. Trofast, G. Westergren-Thorsson (Lund, Sweden)
| |
Salmeterol has no effect on increased bronchial responsiveness induced by organic dust exposure in healthy volunteers
A. Ek, B. M. Sundblad, L. Palmberg, K. Larsson (Stockholm, Sweden)
| |
A multi-centre doubleblind randomised study examining the clinical outcome of treatment of the first asthma exacerbation with salmeterol xinafoate/fluticasone propionate combination product versus prednisolone
A. J. M. Schreurs, H. L. M. van Helmond, J. H. E. Schijen, L. P. M. Greefhorst, P. G. H. Mulder (Hertogenbosch, Roosendaal, Tilburg, Hengelo, Rotterdam, The Netherlands)
| |
Identifying risk factors affecting the first asthma exacerbation rate in a multi-centre study examining the use of salmeterol xinafoate/fluticasone propionate
A. J. M. Schreurs, H. L. M. van Helmond, J. H. E. Schijen, L. P. M. Greefhorst, P. G. H. Mulder (Hertogenbosch, Roosendaal, Tilburg, Hengelo, Rotterdam, The Netherlands)
| |
The effects of treatment with fluticasone propionate alone and combination with salmeterol on asthma control and airway inflammation
K. Lin, C. Wang, K. Sun, G. Qian (Chongqing, China)
| |
Adherence to treatment with β2 long-acting+inhaled steroid from two distinct device and from an unique device in mild-to-moderate asthma: preliminary results of a double-blind telephonic investigation
R. W. Dal Negro, R. Bisato, C. Micheletto, S. Tognella (Bussolengo, Italy)
| |
Quality of life questionnaire and indirect provocation test as measure of therapeutical effects of fluticasone and salmeterol in asthma
P. A. Postolache, O. P. Petrescu (Iasi, Romania)
| |
Formoterol/budesonide (FBC) in the treatment of acute exacerbation of COPD
M. Cazzola, A. Salzillo, C. De Giglio, P. Noschese, G. D[ssqoute]Amato (Naples, Italy)
| |